SciDEX
Main
🏠Dashboard🔬Analyses📈Exchange🏛The Agora🗣Debates🔍Research Gaps⚖Compare
Knowledge
📖Wiki🕸Knowledge Graph🗺Atlas📦Artifacts🧬Protein Designs📄Papers📓Notebooks🔎Search
System
🏛Senate⚔Quests💰Resources🔨Forge💹Economics📊Experiments🤖Agents🚦Status📑Docs
Info
ℹVision⭐Showcase📽Demo
📖

AMDX-2011P Retinal Amyloid Tracer in Alzheimer's Disease

wiki page Created: 2026-04-02 13:40:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-amdx-2011p-retinal-
Related Entities
clinical-trials-amdx-2011p-retinal-amyloid-tracer-ad
Metadata
slugclinical-trials-amdx-2011p-retinal-amyloid-tracer-ad
entity_typeclinical
kg_node_idNone
🌍 Provenance Graph 1 nodes, 0 edges

No provenance edges found

Linked Artifacts (389)
related🧪HSP90-Tau Disaggregation Complex Enhancement80%
related🧪VCP-Mediated Autophagy Enhancement80%
related🧪LRP1-Dependent Tau Uptake Disruption80%
related🧪Extracellular Vesicle Biogenesis Modulation80%
related🧪Synaptic Vesicle Tau Capture Inhibition80%
related🧪TREM2-mediated microglial tau clearance enhancement80%
related🧪Trans-Synaptic Adhesion Molecule Modulation80%
related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia80%
related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation80%
related🧪Complement C1QA Spatial Gradient in Cortical Layers80%
related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation80%
related🧪APOE Isoform Expression Across Glial Subtypes80%
related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro80%
related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli80%
related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK80%
related🧪Prefrontal sensory gating circuit restoration via PV interne80%
related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna80%
related🧪Gamma entrainment therapy to restore hippocampal-cortical sy80%
see_also📖Alzheimer's Disease Biomarkers80%
see_also📖ASL Perfusion Biomarkers for Alzheimer's Disease80%
see_also📖Digital Biomarkers for Alzheimer's Disease80%
see_also📖Dried Blood Spot Biomarker Test for Alzheimer's Disease80%
see_also📖DTI Biomarkers for Alzheimer's Disease80%
see_also📖EEG Biomarkers for Alzheimer's Disease80%
see_also📖Eye-Tracking Digital Markers in Alzheimer's Disease80%
see_also📖Gait Biomarkers for Alzheimer's Disease80%
see_also📖GFAP in Alzheimer's Disease80%
see_also📖Inflammatory Biomarkers in Alzheimer's Disease80%
see_also📖Neurogranin - Alzheimer's Disease Biomarker80%
see_also📖NPTX1 and NPTXR CSF Markers Predict Alzheimer's Disease80%
see_also📖Ocular Fluid Biomarkers for Alzheimer's Disease80%
see_also📖Olfactory Biomarkers for Alzheimer's Disease80%
see_also📖Plasma Phospho-Tau Ratio Diagnostic Panel for Alzheimer'80%
see_also📖Salivary Biomarkers for Alzheimer's Disease80%
see_also📖Sleep Biomarkers for Alzheimer's Disease80%
see_also📖Speech and Cognitive Biomarkers for Alzheimer's Disease80%
see_also📖Synaptic Biomarkers for Alzheimer's Disease80%
see_also📖Tear Film Biomarkers in Alzheimer's Disease80%
see_also📖VILIP-1 and YKL-40 - Alzheimer's Disease Biomarkers80%
see_also📖Diffuse Amyloid Deposits in Alzheimer's Disease80%
see_also📖ACP-204 for Alzheimer's Disease Psychosis (NCT06159673)80%
see_also📖ASN90 Phase 2 Trial - Early Alzheimer's Disease (NCT05680%
see_also📖BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer80%
see_also📖BMS-986368 Phase 2 - Agitation in Alzheimer's Disease80%
see_also📖BMS-986446 Phase 2 Trial for Early Alzheimer's Disease80%
see_also📖Centella asiatica Phase 1 Trial for Alzheimer's Disease80%
see_also📖Escitalopram for Agitation in Alzheimer's Disease (NCT080%
see_also📖EX039 Phase 2 (NCT05413655) — Oral Therapeutic for Alzheimer80%
see_also📖ExPlas — Exercise Plasma Transfusion for Alzheimer's Di80%
see_also📖Fasudil for Early Alzheimer's Disease (FEAD) - NCT0636280%
see_also📖[F-18]Flornaptitril PET - Phase 3 for Alzheimer's Disea80%
see_also📖Foralumab Phase 2 Trial for Alzheimer's Disease80%
see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%
see_also📖Guanfacine NorAD - Phase 3 Trial for Alzheimer's Diseas80%
see_also📖IGC-AD1 for Agitation in Alzheimer's Disease (NCT05543680%
see_also📖ITI-1284 for Alzheimer's Disease Psychosis (NCT0654083380%
see_also📖KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's D80%
see_also📖Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Dise80%
see_also📖LEAF Trial - THC+CBD for Alzheimer's Disease Agitation 80%
see_also📖NCT03875638 - Levetiracetam for Alzheimer's Disease80%
see_also📖LHP588: P. gingivalis Targeting for Alzheimer's Disease80%
see_also📖MAR Polypill for Alzheimer's Disease (NCT06597058)80%
see_also📖Masupirdine for Alzheimer's Disease Agitation80%
see_also📖Masupirdine for Agitation in Alzheimer's Disease (NCT0580%
see_also📖MK-2214 for Early Alzheimer's Disease80%
see_also📖Nabilone for Agitation in Alzheimer's Disease (NCT0451680%
see_also📖NAB-IT: Nabilone for Agitation in Alzheimer's Disease80%
see_also📖TRAILBLAZER-ALZ 3 (NCT05026866) — Donanemab for Preclinical 80%
see_also📖GV1001 for Moderate to Severe Alzheimer's Disease (NCT080%
see_also📖Biogen Alzheimer's Disease Phase 2 Trial (NCT05399888)80%
see_also📖Synaptic Therapy Alzheimer's Research Trial (START): A 80%
see_also📖CBD (Cannabidiol) for Alzheimer's Disease Agitation - N80%
see_also📖GSK4527226 (AL101) for Early Alzheimer's Disease (NCT0680%
see_also📖The Alzheimer's Disease Tau Platform Clinical Trial (NC80%
see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%
see_also📖KarXT for Alzheimer's Disease Cognitive Impairment - MI80%
see_also📖A Phase 3, Randomised, Double-blinded, Placebo-controlled St80%
see_also📖Novartis Alzheimer's Disease Phase 2 Trial (NCT0709451680%
see_also📖Master Screening Study to Determine Individuals With Potenti80%
see_also📖NRTIs for Alzheimer's Disease - Phase 1 (NCT07210528)80%
see_also📖X/T + X-EC + Lecanemab Phase 2 (NCT07212062) — Alzheimer80%
see_also📖DMB-I (Latrepirdine) Phase 3 (NCT07251023) — Alzheimer'80%
see_also📖Exciva Alzheimer's Disease Phase 2/3 Trial80%
see_also📖NCT06582706: Nicotinic Acid for Alzheimer's Disease80%
see_also📖NCT07262645: Near-Infrared Light Therapy for Mild-Moderate A80%
see_also📖NRTIs for Alzheimer's Disease: Targeting Type-I Interfe80%
see_also📖ONO-2020 for Alzheimer's Disease (NCT06881836)80%
see_also📖NCT06803823 - ONO-2020 for Agitation in Alzheimer's Dis80%
see_also📖Ozanimod for Alzheimer's Disease (NCT06862960)80%
see_also📖Piromelatine 20 mg for Mild Dementia Due to Alzheimer's80%
see_also📖PLX5622 CSF1R Inhibitor Trial in Early Alzheimer's Dise80%
see_also📖Probiotics in Mild Alzheimer's Disease (NCT06181513)80%
see_also📖Recombinant Human Serum Albumin for Alzheimer's Disease80%
see_also📖Rotigotine and Rivastigmine Combination Therapy for Alzheime80%
see_also📖Senicapoc Alzheimer's Disease Trial - NCT0480424180%
see_also📖SHR-1707 for Alzheimer's Disease (NCT06199037)80%
see_also📖Siponimod for Alzheimer's Disease (NCT06639282)80%
see_also📖SNIFF-Combo: Intranasal Insulin + Empagliflozin for Alzheime80%
see_also📖SToP-AD: Suvorexant for Alzheimer's Disease Prevention80%
see_also📖TRAP-AD: Transcranial Photobiomodulation for Alzheimer'80%
see_also📖VY7523 Phase 1/2 Alzheimer's Disease Trial80%
see_also📖Alzheimer's Disease Mechanism Index80%
see_also📖APOE Lipid Metabolism Pathway in Alzheimer's Disease80%
see_also📖CD33 Siglec Receptor Dysfunction Alzheimer's Disease Ca80%
see_also📖Cholinergic System Degeneration in Alzheimer's Disease80%
see_also📖EEG Microstates in Alzheimer's Disease80%
see_also📖Endolysosomal Pathway in Alzheimer's Disease80%
see_also📖Geniposide for Alzheimer's disease - immune biomarker t80%
see_also📖Glymphatic System in Alzheimer's Disease80%
see_also📖Locus Coeruleus Degeneration in Alzheimer's Disease80%
see_also📖Metal Ion Homeostasis in Alzheimer's Disease80%
see_also📖Mitochondrial Dysfunction in Alzheimer's Disease Pathwa80%
see_also📖Neuroinflammation in Alzheimer's Disease80%
see_also📖Neuroinflammation Hypothesis in Alzheimer's Disease80%
see_also📖Neurovascular Dysfunction in Alzheimer's Disease: Integ80%
see_also📖NLRP3 Inflammasome Pathway in Alzheimer's Disease80%
see_also📖Sex-Specific Mechanisms in Alzheimer's Disease80%
see_also📖Sleep and Circadian Dysfunction in Alzheimer's Disease80%
see_also📖Sporadic Alzheimer's Disease Pathway80%
see_also📖Synaptic Loss in Alzheimer's Disease Pathway80%
see_also📖Tau Kinase-Phosphatase Balance in Alzheimer's Disease80%
see_also📖Tau Kinase Signaling Cascade in Alzheimer's Disease80%
see_also📖Ubiquitin-Proteasome System Dysfunction in Alzheimer's 80%
see_also📖Vascular Dementia Mechanisms — Overlap with Alzheimer's80%
see_also📖Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzh80%
see_also📖Cannabidiol for Alzheimer's Disease Prevention (NCT058280%
see_also📖EI-1071 Immunomodulator for Alzheimer's Disease (NCT06780%
see_also📖NCT07477431 - Levetiracetam for Persons at Risk for Alzheime80%
see_also📖TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di80%
see_also📖APOE4 and Alzheimer's Disease Risk80%
related🧪Cell-Type Specific TREM2 Upregulation in DAM Microglia72%
related🧪GFAP-Positive Reactive Astrocyte Subtype Delineation72%
related🧪Complement C1QA Spatial Gradient in Cortical Layers72%
related🧪Excitatory Neuron Vulnerability via SLC17A7 Downregulation72%
related🧪APOE Isoform Expression Across Glial Subtypes72%
related🧪ACSL4-Driven Ferroptotic Priming in Disease-Associated Micro72%
related🧪Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli72%
related🧪SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK72%
mentions🧪APOE Isoform Conversion Therapy70%
mentions🧪APOE Isoform Expression Across Glial Subtypes70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
related🧫Protein Aggregation Kinetic Validation Results70%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
related🧫Experiment Validation: In vitro ThT Assay70%
related🧫ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De70%
related🧫Animal Model Comparison for Neurodegenerative Disease Therap70%
related🧫Endocannabinoid System Dysfunction Validation in Parkinson&#70%
related🧫Glymphatic-Circadian Axis Enhancement Therapy for Parkinson&70%
related🧫Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag70%
related🧫Neural Oscillation Dysfunction Validation in Parkinson'70%
related🧫Oligodendrocyte-Myelin Dysfunction Validation in Parkinson&#70%
related🧫Proteasome-Ubiquitin System Dysfunction Validation in Parkin70%
related🧫Protein Aggregation Kinetic Validation Results70%
related🧫Purinergic Signaling Dysfunction Validation in Parkinson70%
related🧫Regulated Necrosis Validation Study in Parkinson's Dise70%
related🧫Stress Granule Dysfunction Validation in Parkinson's Di70%
related🧫Experiment Validation: In vitro ThT Assay70%
related🧪APOE Isoform Conversion Therapy63%
mentions🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer60%
mentions🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides60%
mentions🧪Competitive APOE4 Domain Stabilization Peptides60%
related🧫s:** - Test whether HCN1 knockout specifically in EC layer I60%
related🧫Proposed experiment from debate on Synaptic pruning by micro60%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%
related🧫4R-Tau Targeting Therapies for PSP and CBS60%
related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi60%
related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau60%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti60%
related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?60%
related🧫Anti-Tau Immunotherapy Dosing Optimization60%
related🧫ApoE4 Function in Alzheimer's Disease60%
related🧫Experiment: Autoimmune Hypothesis Testing in AD60%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration60%
related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#60%
related🧫Blood-Based Biomarker Panel for Early AD Detection60%
related🧫tACS Connectivity Trial in Early Alzheimer's60%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD60%
related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 60%
related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M60%
related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera60%
related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera60%
related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa60%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation60%
related🧫Gap Junction Dysfunction Validation in Parkinson's Dise60%
related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas60%
related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise60%
related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech60%
related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr60%
related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis60%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress60%
related🧫Neural Stem Cell Therapy for Alzheimer's Disease60%
related🧫Normal Aging to Alzheimer's Disease Transition Trigger 60%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 60%
related🧫Prion Strain Diversity and Selective Vulnerability60%
related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease60%
related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#60%
related🧫Sex Differences in Alzheimer's Disease — mechanisms and60%
related🧫Sleep Disruption and Alzheimer's Disease — mechanism an60%
related🧫Traumatic Brain Injury and Alzheimer's Disease Relation60%
related🧫Tau ASO Therapy60%
related🧫Microglial TREM2 Agonist In Vivo Efficacy60%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia60%
related🧫Vascular Contribution to Alzheimer's Disease — Beyond A60%
related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol60%
related🧫Viral Infections and Alzheimer's Disease — causal mecha60%
see_also📖Age-Sensitive Cortical Vulnerability in Parkinson's Dis60%
see_also📖Tau Consortium60%
see_also📖Neurodegeneration60%
see_also📖Dementia Australia60%
see_also📖a2m60%
see_also📖ABCA1 - ATP-Binding Cassette Transporter A160%
see_also📖ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member 160%
see_also📖ABCD3 Gene60%
see_also📖ABCG1 Gene60%
see_also📖ACTB Gene60%
see_also📖AGER Gene60%
see_also📖ambra160%
see_also📖Packard Center for ALS Research60%
see_also📖Proteome Atlas for Neurodegenerative Diseases60%
related🧪Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro55%
related🧪Selective APOE4 Degradation via Proteolysis Targeting Chimer54%
related🧪Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides54%
related🧪Competitive APOE4 Domain Stabilization Peptides54%
related🧫s:** - Test whether HCN1 knockout specifically in EC layer I54%
related🧫Proposed experiment from debate on Synaptic pruning by micro54%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%
related🧫4R-Tau Targeting Therapies for PSP and CBS54%
related🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi54%
related🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau54%
related🧫Why Does Amyloid Removal Only Slow Decline 27%? — Mechanisti54%
related🧫Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?54%
related🧫Anti-Tau Immunotherapy Dosing Optimization54%
related🧫ApoE4 Function in Alzheimer's Disease54%
related🧫Experiment: Autoimmune Hypothesis Testing in AD54%
related🧫Autophagy Enhancement Drug Screening for Neurodegeneration54%
related🧫Biomarker-Guided Sequential Therapy Selection in Alzheimer&#54%
related🧫Blood-Based Biomarker Panel for Early AD Detection54%
related🧫tACS Connectivity Trial in Early Alzheimer's54%
related🧫Brain Connectivity-Targeted tACS Trial in Early AD54%
related🧫Experimental: CAAR-T Cell Therapy for Autoantibody-Mediated 54%
related🧫Cognitive Reserve Mechanisms in Alzheimer's Disease — M54%
related🧫Cholinergic System Dysfunction in DLB — Mechanisms and Thera54%
related🧫Down Syndrome Alzheimer's Disease: Mechanisms and Thera54%
related🧫Epigenetic Regulation Dysfunction in Alzheimer's and Pa54%
related🧫FTLD-Tau vs FTLD-TDP In Vivo Biomarker Differentiation54%
related🧫Gap Junction Dysfunction Validation in Parkinson's Dise54%
related🧫Lifestyle Intervention Mechanisms in Alzheimer's Diseas54%
related🧫Metal Ion Homeostasis Dysregulation in Alzheimer's Dise54%
related🧫Microbiome-Gut-Brain Axis in Alzheimer's Disease — mech54%
related🧫Microglial Aging and Immune Memory in Neurodegeneration — Tr54%
related🧫Migraine Cortical Hyperexcitability and Alzheimer's Dis54%
related🧫Mixed Pathology Effects on Parkinson's Disease Progress54%
related🧫Neural Stem Cell Therapy for Alzheimer's Disease54%
related🧫Normal Aging to Alzheimer's Disease Transition Trigger 54%
related🧫CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs 54%
related🧫Prion Strain Diversity and Selective Vulnerability54%
related🧫SCFA-Mediated Neuroinflammation in Alzheimer's Disease54%
related🧫Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer&#54%
related🧫Sex Differences in Alzheimer's Disease — mechanisms and54%
related🧫Sleep Disruption and Alzheimer's Disease — mechanism an54%
related🧫Traumatic Brain Injury and Alzheimer's Disease Relation54%
related🧫Tau ASO Therapy54%
related🧫Microglial TREM2 Agonist In Vivo Efficacy54%
related🧫TREM2 Function in Alzheimer's Disease — From Risk Varia54%
related🧫Vascular Contribution to Alzheimer's Disease — Beyond A54%
related🧫Vascular Contributions to Alzheimer Disease and Mixed Pathol54%
related🧫Viral Infections and Alzheimer's Disease — causal mecha54%
mentions🧪HSP90-Tau Disaggregation Complex Enhancement50%
mentions🧪VCP-Mediated Autophagy Enhancement50%
mentions🧪LRP1-Dependent Tau Uptake Disruption50%
mentions🧪Extracellular Vesicle Biogenesis Modulation50%
mentions🧪Prefrontal sensory gating circuit restoration via PV interne50%
mentions🧪Synaptic Vesicle Tau Capture Inhibition50%
mentions🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna50%
mentions🧪TREM2-mediated microglial tau clearance enhancement50%
mentions🧪Gamma entrainment therapy to restore hippocampal-cortical sy50%
mentions🧪Trans-Synaptic Adhesion Molecule Modulation50%
mentions🧫AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi50%
mentions🧫AD Combination Therapy Trial: Anti-Aβ + Anti-Tau50%
mentions🧫Sex Differences in Alzheimer's Disease — mechanisms and50%
mentions🧪APOE4 Allosteric Rescue via Small Molecule Chaperones50%
mentions🧪Interfacial Lipid Mimetics to Disrupt Domain Interaction50%
mentions🧪Targeted APOE4-to-APOE3 Base Editing Therapy50%
mentions🧪Glymphatic System-Enhanced Antibody Clearance Reversal50%
mentions🧪SASP-Driven Aquaporin-4 Dysregulation50%
mentions🧪Aquaporin-4 Polarization Rescue50%
mentions🧪Palmitoylation-Targeted BACE1 Trafficking Disruptors50%
mentions🧪Complement C1q Mimetic Decoy Therapy50%
mentions🧪Complement C1q Subtype Switching50%
mentions🧪Sphingolipid Metabolism Reprogramming50%
mentions🧪Ephrin-B2/EphB4 Axis Manipulation50%
mentions🧪Stress Granule Phase Separation Modulators50%
mentions🧪Phase-Separated Organelle Targeting50%
mentions🧪RNA Granule Nucleation Site Modulation50%
mentions🧪HCN1-Mediated Resonance Frequency Stabilization Therapy50%
mentions🧪Heat Shock Protein 70 Disaggregase Amplification50%
mentions🧪Glial Glycocalyx Remodeling Therapy50%
mentions🧪Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem50%
mentions🧪Lysosomal Positioning Dynamics Modulation50%
mentions🧪Tau-Independent Microtubule Stabilization via MAP6 Enhanceme50%
mentions🧪Mitochondrial Calcium Buffering Enhancement via MCU Modulati50%
mentions🧪Mitochondrial Transfer Pathway Enhancement50%
mentions🧪Netrin-1 Gradient Restoration50%
mentions🧪Microglial Purinergic Reprogramming50%
mentions🧪Purinergic P2Y12 Inverse Agonist Therapy50%
mentions🧪PARP1 Inhibition Therapy50%
mentions🧪Arginine Methylation Enhancement Therapy50%
mentions🧪Mitochondrial-Lysosomal Contact Site Engineering50%
mentions🧪Reelin-Mediated Cytoskeletal Stabilization Protocol50%
mentions🧪Cryptic Exon Silencing Restoration50%
mentions🧪Glycine-Rich Domain Competitive Inhibition50%
mentions🧪Cross-Seeding Prevention Strategy50%
mentions🧪APOE4-Selective Lipid Nanoemulsion Therapy50%
mentions🧪Retinal Vascular Microcirculation Rescue50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying digital biomarkers and ai50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬What are the mechanisms underlying blood-brain barrier trans50%
related🔬What are the mechanisms underlying apoe4 structural biology 50%
related🔬What are the mechanisms underlying digital biomarkers and ai50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬What are the mechanisms underlying what are the mechanisms b50%
related🔬Investigate how lipid raft composition (cholesterol metaboli50%
related🔬Analyze circuit-level changes in neurodegeneration using All50%
related🔬The disease-associated microglia (DAM) phenotype involves TR50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Is disrupted sleep a cause or consequence of neurodegenerati50%
related🔬Comprehensive analysis of immune cell subtypes in neurodegen50%
related🔬What cell types are most vulnerable in Alzheimers Disease ba50%
related🔬What cell types are most vulnerable in Alzheimer's Dise50%
related🔬Cell type vulnerability in Alzheimers Disease (SEA-AD transc50%
related🔬Investigate prion-like spreading of tau pathology through co50%
related🔬SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas50%
related🔬What are the most promising therapeutic strategies for targe50%
related🔬How to break the GBA-alpha-synuclein bidirectional loop for 50%
related🔬Can gut-brain axis modulation prevent or slow Alzheimer'50%
related🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph50%
related🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br50%
related🔬APOE4 differs from APOE3 by C112R causing domain interaction50%
related🔬Can speech, gait, retinal imaging, sleep, and smartphone dat50%
related🧪APOE Isoform Conversion Therapy50%
related🔬What are the mechanisms underlying selective vulnerability o50%
related🔬What are the mechanisms underlying autophagy-lysosome pathwa50%
related🔬What are the mechanisms underlying synaptic pruning by micro50%
see_also📖al002-trem2-agonist-alzheimers45%
mentions🔬What cell types are most vulnerable in Alzheimer's Dise40%
mentions🔬What are the most promising therapeutic strategies for targe40%
mentions🔬Can gut-brain axis modulation prevent or slow Alzheimer'40%
mentions🔬What cell types are most vulnerable in Alzheimers Disease ba40%
mentions🔬How to break the GBA-alpha-synuclein bidirectional loop for 40%
mentions🔬Investigate how lipid raft composition (cholesterol metaboli40%
mentions🔬Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% br40%
mentions🔬APOE4 differs from APOE3 by C112R causing domain interaction40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬What are the mechanisms underlying what are the mechanisms b40%
mentions🔬The disease-associated microglia (DAM) phenotype involves TR40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Is disrupted sleep a cause or consequence of neurodegenerati40%
mentions🔬Comprehensive analysis of immune cell subtypes in neurodegen40%
mentions🔬Astrocytes adopt A1 (neurotoxic) and A2 (neuroprotective) ph40%
mentions🔬Can speech, gait, retinal imaging, sleep, and smartphone dat40%
related🧪HSP90-Tau Disaggregation Complex Enhancement40%
related🧪VCP-Mediated Autophagy Enhancement40%
related🧪Retinal Vascular Microcirculation Rescue40%
related🧪LRP1-Dependent Tau Uptake Disruption40%
related🧪Extracellular Vesicle Biogenesis Modulation40%
related🧪Prefrontal sensory gating circuit restoration via PV interne40%
related🧪Synaptic Vesicle Tau Capture Inhibition40%
related🧪Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna40%
related🧪TREM2-mediated microglial tau clearance enhancement40%
related🧪Gamma entrainment therapy to restore hippocampal-cortical sy40%
related🧪Trans-Synaptic Adhesion Molecule Modulation40%

💬 Discussion

SciDEX — scidex.ai — Dashboard | Mission Control | Status | How it Works | GitHub